These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23016917)
1. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917 [TBL] [Abstract][Full Text] [Related]
2. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions. Shooshtarizadeh T; Rahimi M; Movahedinia S Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669 [TBL] [Abstract][Full Text] [Related]
3. p63 expression in giant cell-containing lesions of bone and soft tissue. de la Roza G Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272 [TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965 [TBL] [Abstract][Full Text] [Related]
5. Giant cell tumor of bone express p63. Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114 [TBL] [Abstract][Full Text] [Related]
6. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience. Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519 [TBL] [Abstract][Full Text] [Related]
8. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques]. Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573 [TBL] [Abstract][Full Text] [Related]
9. Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Zhou Q; Chang H; Zhang H; Han Y; Liu H Diagn Pathol; 2012 Sep; 7():119. PubMed ID: 22963430 [TBL] [Abstract][Full Text] [Related]
10. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained. Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342 [TBL] [Abstract][Full Text] [Related]
11. Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers. Horvai AE; Roy R; Borys D; O'Donnell RJ Mod Pathol; 2012 Nov; 25(11):1452-61. PubMed ID: 22766796 [TBL] [Abstract][Full Text] [Related]
13. A Comparative Analysis of p63 Expression in Giant Cell Tumour (GCT), Central Giant Cell Granuloma (CGCG) and Peripheral Giant Cell Granuloma (PGCG). Nagar SR; Bansal S; Jashnani K; Sinha A; Desai RS Head Neck Pathol; 2020 Sep; 14(3):733-741. PubMed ID: 31873936 [TBL] [Abstract][Full Text] [Related]
14. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions. Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma. Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430 [TBL] [Abstract][Full Text] [Related]
16. The co-expression of cytokeratin and p63 in epithelioid angiosarcoma of the parotid gland: a diagnostic pitfall. Lin XY; Liu Y; Zhang Y; Yu JH; Wang EH Diagn Pathol; 2012 Sep; 7():118. PubMed ID: 22943673 [TBL] [Abstract][Full Text] [Related]
17. TGF-beta isoform and receptor expression in giant cell tumor and giant cell lesions of bone. Franchi A; Benvenuti S; Masi L; Malentacchi C; Arganini L; Brandi ML; Santucci M Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):170-5. PubMed ID: 11396635 [TBL] [Abstract][Full Text] [Related]
18. Occasional staining for p63 in malignant vascular tumors: a potential diagnostic pitfall. Kallen ME; Nunes Rosado FG; Gonzalez AL; Sanders ME; Cates JM Pathol Oncol Res; 2012 Jan; 18(1):97-100. PubMed ID: 21667345 [TBL] [Abstract][Full Text] [Related]
19. Is Core Needle Biopsy Reliable in Differentiating Between Aggressive Benign and Malignant Radiolucent Bone Tumors? Hegde V; Burke ZDC; Park HY; Zoller SD; Johansen D; Kelley BV; Levine B; Motamedi K; Federman NC; Seeger LL; Nelson SD; Bernthal NM Clin Orthop Relat Res; 2018 Mar; 476(3):568-577. PubMed ID: 29529643 [TBL] [Abstract][Full Text] [Related]
20. p63 as a prognostic marker for giant cell tumor of bone. Yanagisawa M; Kakizaki H; Okada K; Torigoe T; Kusumi T Ups J Med Sci; 2013 Mar; 118(1):23-8. PubMed ID: 23033898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]